Clinical Trials Logo

Vestibular Schwannoma clinical trials

View clinical trials related to Vestibular Schwannoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05116878 Terminated - Clinical trials for Vestibular Schwannoma

Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

EFFORTS
Start date: November 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is to develop a therapeutic agent to help improve facial nerve outcomes and ultimately improve long-term quality-of-life following surgical resection of vestibular schwannomas. It is possible the therapeutic agent may impact tumor control rates as well, and this will also be studied. Using rigorous scientific methods, we will assess whether these factors are impacted by the treatment agent (Omega-3) versus placebo control (cellulose).

NCT ID: NCT02282917 Terminated - Meningioma Clinical Trials

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Start date: December 2015
Phase: Early Phase 1
Study type: Interventional

This will be a multi-center, proof of concept phase 0 study to assess the suppression of p-AKT in Vestibular Schwannoma (VS) and meningiomas by AR-42 in adult patients undergoing tumor resection. AR-42 is a small molecule which crosses the blood brain barrier (BBB) in rodents, but the investigators are not certain yet if it will penetrate human VS. Meningiomas are outside the BBB, but seem to be unusually resistant to all current medical treatments. The primary endpoint of the bioactivity of suppression of p-AKT by AR-42 was selected as drug activity seems more informative than bioavailability. Our preclinical data and others have shown dose dependent suppression of p-AKT by AR-42 in both VS and meningiomas.